Stock Financial Ratios, Dividends, Split History

HMNY / Helios and Matheson Analytics Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Price0.34
Volume20,262,000.00
Market Cap ($M)32.24
Enterprise Value ($M)-10.28
Book Value ($M)-2.77
Book Value / Share-0.03
Price / Book-1.20
NCAV ($M)-109.64
NCAV / Share-1.33
Price / NCAV-0.26
Share Statistics
Percentage Of Additional Shares Outstanding 1
Percentage Of Shares Outstanding 1
Common Stock Shares Outstanding 23,981,253
Common Shares Outstanding 52,996,631
Scoring Models
Piotroski F-Score0.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)254.50
Return on Assets (ROA)-10.40
Return on Equity (ROE)-12.63
Balance Sheet (mrq) ($M)
Assets177.09
Liabilities179.86
Quick Ration/a
Current Ratio0.39
Income Statement (mra) ($M)
Subscription Revenue5,929,267.00
Advertising Revenue0.00
Consulting Revenue4,512,300.00
Revenues10,441,567.00
Operating Income-56.02
Net Income-150.82
Earnings Per Share Diluted-17.46
Earnings Per Share Basic And Diluted-17.46
Earnings Per Share Basic-17.46
Cash Flow Statement (mra) ($M)
Cash From Operations-27.38
Cash from Investing-25.57
Cash from Financing-25.57
Identifiers and Descriptors
CUSIP42327L200
Central Index Key (CIK)1040792
Related CUSIPS
42327L101

Split History

Stock splits are used by Helios and Matheson Analytics Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
HMNY: Helios and Matheson Analytics Analysis and Research Report

2018-05-19 - Asif

Business Overview The company provide high quality information technology, or IT, services and solutions including a range of technology platforms focusing on big data, business intelligence, and consumer-centric technology. More recently, to provide greater value to stockholders, the Company has sought to expand its business primarily through acquisitions that leverage its capabilities and expertise. As of March 31, 2018, the Company owned 81.2%, and as of the date of this report the Company owns 91.8%, of the outstanding shares of MoviePass (excluding outstanding MoviePass options and warrants). MoviePass is the premiere movie theater subscription service in the United States which provides its subscribers the ability to view up to one new movie title per day for one monthly subscription price. The company's more than 2 million subscribers have access to see films in over 91% of U.S movie theaters. By the end of April 2018, the company implemented certain measures ...

Related Articles

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

STML: Stemline Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Stemline Therapeutics was incorporated under the laws of the State of Delaware in August 2003. Stemline Therapeutics is a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and potentially commercializing innovative oncology therapeutics that target difficult to treat cancers. The company's clinical pipeline includes: SL-401, SL-801, and SL-701. SL-401 pivotal data; plans for registration and potential commercialization: SL-401 has completed a pivotal trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN, and has successfully met the primary endpoint of the trial. SL-401 is a targeted therapy directed to the interleukin-3 receptor-a, or CD123. SL-401 was granted breakthrough therapy designation, or BTD, by the U.S. Food and Drug Administration, or FDA, for the treatment of patients with BPDCN. Based on the trial results and other data, the company expect to complete submission of a rolling Biologics License...

Related News Stories

Will Rising Rates Derail This 11.95% Yielding REIT?

2018-06-16 seekingalpha
The Fed Chair is very sanguine on the outlook for the U.S. economy going forward, supporting his intent to proffer two more raises this year. (60-0)

Stocks To Watch: Don't Sleep On Vienna

2018-06-16 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. (526-2)

Top Consumer Company Near 52-Week Low Yields 5.89%: Seeks Redemption In India

2018-06-13 seekingalpha
Anyone paying even the least amount of attention to the tobacco industry is cognizant of the fact that Philip Morris (PM) is putting a full-court press on getting its IQOS smokeless product to surpass, supplant and replace tobacco products like cigarettes. (63-1)

The Bull Case For Helios And Matheson Analytics

2018-06-12 seekingalpha
While most analysts appear to be bearish on HMNY, a buying opportunity exists for this beaten-down stock. (7-5)

Forget The Past: A Unique Opportunity Has Presented Itself In Helios And Matheson

2018-06-07 seekingalpha
Editor's note: Seeking Alpha is proud to welcome Plato Management as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » (7-9)

CUSIP: 42327L200